Tuberculosis (TB)

WHO and partners announce new policies and developments to end TB at the 47th Union World Conference on Lung Health

The World Health Organization (WHO) was joined by partners today, at a press briefing on new policies and developments to end TB. Key areas of focus included: policy guidance on delamanid for children and adolescents, a new toolkit on developing national TB research plans, addressing zoonotic TB, and the first Primer on TB published in Nature Reviews Disease Primers. The briefing was moderated by Dr Mario Raviglione, Director of the WHO Global TB Programme. Key speakers included: Dr Christian Lienhardt, Team Leader, Research for TB Elimination at WHO, Dr Paula Fujiwara, Scientific Director at The Union, and Dr Madhukar Pai, Director at McGill Global Health Programs.

Toolkit for developing national TB research plans

WHO released a new toolkit today to support national TB programmes in developing and implementing a prioritized national TB research agenda that will help leverage individual country action to fight TB. Investments in TB research are critical to find better diagnostics, drugs and vaccines to end the TB epidemic by 2030.

Addressing Zoonotic TB

A new factsheet on Zoonotic TB developed jointly by the WHO, The Union, the World Organisation for Animal Health (OIE), and the Food and Agricultural Organisation of the United Nations (FAO), was released today at the press briefing. It outlined key actions needed to prioritize and address zoonotic TB as part of the global Sustainable Development Goals agenda and the WHO End TB Strategy.

First Primer on TB published in Nature Reviews Disease Primers

An international group of top TB experts from several leading institutions published a primer on TB in the journal Nature Reviews Disease Primers. The Primer on TB, the first coverage of this topic by Nature Reviews Disease Primers, provides an authoritative, global perspective for the benefit of biomedical scientists, putting current clinical and translational challenges in tackling the disease into context. It covers recent advances in our understanding of the microbiology, immunology, diagnosis and treatment of TB. The 23-page primer, can be freely downloaded for a 1-month period only. More on this story

Guidance for the use of delamanid in children and adolescents

New guidance has been issued by the World Health Organization on the use of delamanid in children and adolescents. WHO now recommends that the drug may be used on top of the longer (18-24 months) treatment regimen in children and adolescents (6 – 17 years) with MDR-TB.